Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Observational Study of Efficacy and Safety in Chemotherapy After Refractory or Intolerant to Nivolumab Therapy for Unresectable Advanced or Recurrent Gastric Cancer

Next Previous
Trial Profile

Prospective Observational Study of Efficacy and Safety in Chemotherapy After Refractory or Intolerant to Nivolumab Therapy for Unresectable Advanced or Recurrent Gastric Cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Irinotecan; Oxaliplatin; Tipiracil/trifluridine
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms CSPOR GC-01; REVIVE

Most Recent Events

  • 02 Jul 2022 Results of REVIVE substudy (n=395) assessing (efficacy and safety) impacts of salvage chemotherapy after nivolumab therapy, presented at the 24th World Congress on Gastrointestinal Cancer.
  • 03 Mar 2022 New trial record
  • 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top